Literature DB >> 9797662

Causes of blindness in the adult population of the Republic of Ireland.

A Munier1, T Gunning, D Kenny, M O'Keefe.   

Abstract

BACKGROUND/AIM: Blindness in the developed countries affects 3.5 million people. This study was conducted on the causes of blindness in the Republic of Ireland based on the register of the National Council for the Blind of Ireland. The aim was to determine the prevalence of potentially avoidable blindness and to identify its causes.
METHOD: Criteria for registration as blind are in Ireland: best corrected visual acuity of 6/60 (0.1) or less in the better eye or a visual field restricted to 20 degrees or less. Data on 5002 adults 16 years an older registered as blind were analysed. The causes of blindness are classified in 17 diagnostic categories.
RESULTS: The leading causes of blindness are macular degeneration and glaucoma, each accounting for 16% (812 and 795). Cataract accounted for 11% (561), a third of these had an associated cause of blindness and one tenth had a cognitive deficit. Diabetic retinopathy ranked as the 11th cause of blindness and accounted for 3% (147). More than half of the patients were 65 years and older.
CONCLUSION: 25% of blindness was potentially avoidable. The treatable causes were glaucoma and diabetic retinopathy in the working population and glaucoma and cataract over 65 years of age. Glaucoma is the most important, which raises the question of a screening programme. The prevalence of blindness of 3% due to diabetic retinopathy is lower than in most other series.

Entities:  

Mesh:

Year:  1998        PMID: 9797662      PMCID: PMC1722638          DOI: 10.1136/bjo.82.6.630

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  24 in total

1.  Prevalence of diabetic retinopathy in patients with diabetes mellitus diagnosed after the age of 70 years.

Authors:  M Cahill; A Halley; M Codd; N O'Meara; R Firth; D Mooney; R W Acheson
Journal:  Br J Ophthalmol       Date:  1997-03       Impact factor: 4.638

2.  Chronic glaucoma: a preventable cause of blindness.

Authors:  R P Crick
Journal:  Lancet       Date:  1974-02-09       Impact factor: 79.321

Review 3.  The epidemiology of open-angle glaucoma: a review.

Authors:  M C Leske
Journal:  Am J Epidemiol       Date:  1983-08       Impact factor: 4.897

4.  Blindness and visual impairment in an American urban population. The Baltimore Eye Survey.

Authors:  J M Tielsch; A Sommer; K Witt; J Katz; R M Royall
Journal:  Arch Ophthalmol       Date:  1990-02

5.  Recent trends in the registration of blindness and partial sight in Leicestershire.

Authors:  J R Thompson; L Du; A R Rosenthal
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

6.  Blind and partial sight registration in Avon.

Authors:  R H Grey; C J Burns-Cox; A Hughes
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

7.  Costing a community based screening programme for the detection of glaucoma.

Authors:  S J Jones; S A Vernon; L Cater; D J Henry
Journal:  Eye (Lond)       Date:  1990       Impact factor: 3.775

8.  Common causes of blindness and visual handicap in the west of Scotland.

Authors:  I M Ghafour; D Allan; W S Foulds
Journal:  Br J Ophthalmol       Date:  1983-04       Impact factor: 4.638

9.  Blindness in the city of Nottingham (1980-1985).

Authors:  W A Aclimandos; N R Galloway
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

10.  Prevalence of blindness and eye disease: discussion paper.

Authors:  G J Johnson; D C Minassian
Journal:  J R Soc Med       Date:  1989-06       Impact factor: 18.000

View more
  27 in total

1.  Prevention of diabetic blindness.

Authors:  E Stefánsson
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

2.  Long-term Natural History of Atrophy in Eyes with Choroideremia-A Systematic Review and Meta-analysis of Individual-Level Data.

Authors:  Liangbo L Shen; Aneesha Ahluwalia; Mengyuan Sun; Benjamin K Young; Holly K Grossetta Nardini; Lucian V Del Priore
Journal:  Ophthalmol Retina       Date:  2020-03-14

3.  The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis.

Authors:  Elias Zintzaras; Dimitrios Z Chatzoulis; Costas H Karabatsas; Ioannis Stefanidis
Journal:  J Hum Genet       Date:  2005-05-18       Impact factor: 3.172

4.  Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.

Authors:  Erin Lavik; Markus H Kuehn; Andrew J Shoffstall; Kristyn Atkins; Alina V Dumitrescu; Young H Kwon
Journal:  J Ocul Pharmacol Ther       Date:  2016-11-11       Impact factor: 2.671

5.  Statistics of optical coherence tomography data from human retina.

Authors:  Norberto Mauricio Grzywacz; Joaquín de Juan; Claudia Ferrone; Daniela Giannini; David Huang; Giorgio Koch; Valentina Russo; Ou Tan; Carlo Bruni
Journal:  IEEE Trans Med Imaging       Date:  2010-03-18       Impact factor: 10.048

Review 6.  Age-related macular degeneration: cost-of-illness issues.

Authors:  C Oneill; J Jamison; D McCulloch; D Smith
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  The prevalence and causes of visual impairment in Tehran: the Tehran Eye Study.

Authors:  A Fotouhi; H Hashemi; K Mohammad; K H Jalali
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

8.  Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.

Authors:  Hussein O Ammar; H A Salama; M Ghorab; A A Mahmoud
Journal:  AAPS PharmSciTech       Date:  2009-06-18       Impact factor: 3.246

9.  Trends in blind registration in the adult population of the Republic of Ireland 1996-2003.

Authors:  C Kelliher; D Kenny; C O'Brien
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

10.  Experimental myopia increases and scleral crosslinking using genipin inhibits cyclic softening in the tree shrew sclera.

Authors:  Alexander M Levy; Massimo A Fazio; Rafael Grytz
Journal:  Ophthalmic Physiol Opt       Date:  2018-05       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.